The clinical experience to date has indicated a number of barriers to the broad applicability of existing patient- and donor-derived cell-based cancer immunotherapy approaches. The use of a clonal master engineered induced pluripotent stem cell (iPSC) line as a renewable source for the mass production of immune cells offers distinct advantages that address these common barriers, including off-the-shelf availability for broad access to patients and multi-dose administration of homogenous engineered cell products with consistent identity, purity, and potency. In this talk, Dr. Wayne Chu of Fate Therapeutics shares recent clinical data from the company’s allogeneic iPSC-derived NK cell therapies for the treatment of hematologic malignancies.

Watch the talk to learn more about:

• Using master iPSC lines to make universal, off-the-shelf NK cell products
• The importance of multiplexed engineering strategies that incorporate multiple mechanisms of action to eradicate cancer
• Improving immune cell therapy approaches to streamline production and treatment processes and convert the field to drug product paradigm